Penumbra, Inc.
PEN
Positions held
Your positionsPEN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Penumbra operates in the growing medical devices industry, which is expected to expand as healthcare demands increase globally.
- Revenue increased by 4% compared to the prior quarter, reaching $390 million.
- Gross margin improved to 67.9%, up from 67.6% in the previous quarter.
- Penumbra's earnings growth is currently negative at -23.5%, indicating potential challenges in profitability.
- The company's trailing P/E ratio is high at 77.9, suggesting it may be overvalued compared to its earnings.
- The stock has a 'Strong Sell' signal with a score of -28.00, indicating bearish market sentiment.
Fundamentals
| Market cap | $12.51B | Enterprise value | $12.06B | Trailing P/E | 78.01 | Forward P/E | 51.78 |
| PEG | 3.56 | Price / book | 8.17 | Beta | 0.70 | Dividend yield | 0.00% |
| Revenue growth | 14.9% | Earnings growth | -23.5% | Gross margin | 67.8% | Operating margin | 10.5% |
| Profit margin | 10.7% | ROE | 11.4% | ROA | 6.4% | Debt / equity | 0.14 |
| Current ratio | 5.75 | Free cash flow | $161.10M | Analyst recommendation | hold | Mean target | $361.58 |
| 52w high | $362.41 | 52w low | $221.26 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $390M | $375M | $385M | $355M | $339M |
| Op margin | 10.5% | 10.2% | 15.4% | 13.8% | 12.0% |
| Net income | $34.8M | $32.6M | $47.3M | $45.9M | $45.3M |
| Gross margin | 67.9% | 67.6% | 68.0% | 67.8% | 66.0% |
| Gross profit | $265M | $253M | $262M | $240M | $224M |
| Operating income | $41.0M | $38.2M | $59.2M | $48.8M | $40.8M |
- Revenue +4% vs prior quarter ($390M vs $375M).
- Gross margin 67.9% (was 67.6% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.2B | $1.1B | $847M | — |
| Op margin | 13.5% | 7.2% | 8.7% | 0.7% | — |
| Net income | $178M | $14.0M | $91.0M | -$2.0M | — |
| Gross margin | 67.1% | 63.2% | 64.5% | 63.2% | — |
| Gross profit | $942M | $755M | $683M | $535M | — |
| Operating income | $189M | $86.2M | $91.8M | $6.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Penumbra (PEN) Clinical Data Puts Its Valuation Back In Focus
2026-10-08 · Boston Scientific names Joseph Fitzgerald as chief operating officer
2026-10-01 · IART vs. PEN: Which Stock Is the Better Value Option?
2026-09-29 · IART or PEN: Which Is the Better Value Stock Right Now?
2026-09-16 · Reasons to Retain Penumbra Stock in Your Portfolio for Now
2026-09-11 · TFX vs. PEN: Which Stock Is the Better Value Option?
2026-08-26 · TFX or PEN: Which Is the Better Value Stock Right Now?
2026-08-14 · Which Medtech Giant Would Buy Inspire Medical Systems?
2026-08-10 · TFX vs. PEN: Which Stock Is the Better Value Option?
2026-08-06 · Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
2026-07-30 · Penumbra: Q2 Earnings Snapshot
Price (daily)
Full chart · RSI · MACD · patterns